PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

Publication date: Available online 16 July 2019Source: Seminars in Cancer BiologyAuthor(s): Ali S. AlzahraniAbstractPhosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is one of the major cellular signaling pathways play an important role in basic intracellular functions. The PI3K/Akt/mTOR pathway regulates cell proliferation, growth, cell size, metabolism, and motility. Component genes of this pathway were extensively studied and found to be commonly activated in human cancer. Inhibition of this pathway is shown to have better regression of human tumors and being studied in preclinical and evaluated in many clinical trials at various levels. Some inhibitors of this pathway are approved by the food and drug administration after their potent activity and their effect overweighed the toxicities/side effects. This review discusses the recent trends in exploiting the PI3K/Akt/mTOR pathway towards the molecular targeted therapy using small molecule inhibitors in human cancer.
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research